Antiplatelet therapy: Glycoprotein IIb/IIIa receptor antagonists

Drugs of Today

Volumn 35, Issue 6, 1999, Pages 413-418

  Kessler, Steven ^a   Kessler, Diane ^a   Frishman, William H ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BITISTATIN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HIRUDIN; KISTRIN; MONOCLONAL ANTIBODY; ORBOFIBAN; SIBRAFIBAN; SYNTHETIC PEPTIDE; TICLOPIDINE; TIROFIBAN; XEMILOFIBAN;

CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; DRUG BLOOD LEVEL; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; RECEPTOR BLOCKING; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

EID: 0032794595     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.1999.35.6.544927     Document Type: Review

References (26)

1. Frishman, W.H., Klein, M.D., Blaufarb, I. et al. Antiplatelet and other antithrombotic drugs. In: Cardiovas-cular Pharmacotherapeutics. McGraw Hill: New York 1998, 324-79.
2. Davies, M.J. Mechanisms of thrombosis in atherosclerosis. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman, R.W., Hirsch, J., Marder, V.J., Salzman, E.W. (Eds.). J.B. Lippincott: Philadelphia 1994, 1151-63.
3. Hirsch, J., Salzman, E.W., Marder, V.J., Colman, R.W. Overview of the thrombotic process and its therapy. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman, R.W., Hirsch, J., Marder, V.J., Salzman, E.W. (Eds.). J.B. Lippincott: Philadelphia 1994, 1221-37.
4. Lewis, D.H., Davis, J.W., Archibald, D.G. et al. Protective effects of aspirin against myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983, 309: 396-403.
5. Cairns, J.A., Gent, M., Singer, J. et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985, 313: 1369-75.
6. Theroux, P., Ouimet, H., McCans, J. et al. Aspirin, heparin or both to treat acute unstable angina. N Engl J Med 1988, 319: 1105-11.
7. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989, 321: 129-35.
8. Hall, P., Nakamura, S., Maillo, L. et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996, 93: 215-22.
9. Goods, C.M., Al-Shaibi, K.R, Liu, M.W. et al. Comparison of aspirin alone versus aspirin plus ticlopidine after coronary artery stenting. Am J Cardiol 1996, 78: 1042-4.
10. Mellot, M.J., Polokoff, M.A., Bencen, G.H., Bush, L.R. Effects of bitistatin, a snake venom peptide and platelet fibrinogen receptor antagonist in a canine model of thrombolysis and reocclusion. Circulation 1989, 80 (Suppl. II): Abst 216.
11. Yasuda, T., Gold, H.F., Leinbach, R.C. et al. Kistrin, a polypeptide GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation 1991, 83: 1038-47.
12. Scarborough, R.M., Rose, J.W., Hsu, M.A. et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991, 266: 9359-62.
13. Coller, B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of glycoprotein IIb/IIIa complex. J Clin Invest 1985, 76: 101-8.
14. Christopoulos, C., Mackie, I., Lahiri, A. et al. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa. Blood Coagul Fibrinolysis 1993, 4: 729-37.
15. Tcheng, J.E., Ellis, S.G., George, B.S. et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994, 90: 1757-64.
16. 2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990, 86: 651-9.
17. Simoons, M.L., Deboer, M.J., Van den Brand, B.M. et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994, 89: 596-603.
18. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994, 330: 956-61.
19. Lincoff, A.M., Tcheng, J.E., Califf, P.M. et al. for the EPILOG Investigators. Sustained suppression of ischemic complications of coronary intervention by platelet GPIIb/IIIa blockade with abciximab. One-year outcome in the EPILOG trial. Circulation 1999, 99: 1951-8.
20. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. N Engl J Med 1998, 339: 436-43.
21. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II, Integrelin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997, 349: 1422-8.
22. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998, 338: 1498-505.
23. Gibson, C.M., Goel, M., Cohen, D.J. et al. Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1998, 32: 28-34.
24. Kereiakes, D.J., Kleinman, N.S., Ferguson, J.J. et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: Results of a multicenter, placebo-controlled randomized trial. Circulation 1998, 13: 1268-78.
25. Simpfendorfer, C., Kottke-Marchant, K., Lowrie, M. et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997, 96: 76-81.
26. Modi, N.B., Novotny, W., Reimann, J.D., Cannon, C.P., Braunwauld, E. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome. J Clin Pharmacol 1999, 39: 675-84.